Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
ERN applies for the MOVES III grant
ERN applies for the MOVES III grant
LABORATORIOS ERN has applied for the MOVES III program grant for the installation of electric vehicle charging points at its Barcelona headquarters and its center in Sant Andreu de la Barca. The charging points, already operational, reflect its commitment to sustainability and the promotion of electric mobility as a key pillar of its environmental strategy.
Barcelona:
Sant Andreu de la Barca:
With the support of:
noticias relacionadas
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level […]
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section. Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions that improve patients’ lives. […]
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI). Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated […]